Westlab Pharmacy (Westlab Pharmacy, Inc.), Gainesville, FL
Is Westlab Pharmacy (Westlab Pharmacy, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Westlab Pharmacy (Westlab Pharmacy, Inc.) hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH11979 for WESTLAB PHARMACY INC (dba WESTLAB PHARMACY), GAINESVILLE, status Clear and PH27985 for WESTLAB PHARMACY INC (dba WESTLAB PHARMACY), GAINESVILLE, status Clear. The Colorado State Board of Pharmacy also lists nonresident license OSP 5686 for Westlab Pharmacy Inc., Gainesville, FL, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054015792 for WESTLAB PHARMACY INC, GAINESVILLE, FL, status NOT RENEWED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000843 for WESTLAB PHARMACY INC, GAINESVILLE, FL, status ACTIVE (CURRENT), as of Nov 15, 2026.
Has Westlab Pharmacy (Westlab Pharmacy, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jun 26, 2019), 1 warning letter close-out (Jan 10, 2023), 1 state referral letter (Jan 10, 2023) and 1 FMD-145 letter (Jan 10, 2023) for Westlab Pharmacy (Westlab Pharmacy, Inc.). State board actions: no Florida Board of Pharmacy action on licenses PH11979 and PH27985 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Westlab Pharmacy, Inc.; Westlab Pharmacy
- Location
- Gainesville, FL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jan 10, 2023
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 9 observations
- State board records
- License found: PH11979, Clear; PH27985, Clear
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Westlab Pharmacy, Inc., (dba Westlab Pharmacy), a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Jan 10, 2023 | Warning letter close-out | Warning Letter Close Out Issued 01/10/2023 | Not linked by FDA |
| Jan 10, 2023 | State referral letter | State Referral Letter Issued 01/10/2023 | Not linked by FDA |
| Jan 10, 2023 | FMD-145 letter | FMD-145 Letter Issued 01/10/2023 | Not linked by FDA |
| Oct 5, 2021 | Form 483 | 483 Issued 10/05/2021 | FDA copy (archived) |
| Jun 26, 2019 | Warning letter | Warning Letter (06/26/2019) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Westlab Pharmacy, Inc., Gainesville, FL (FEI number 3007426960), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 5, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3007426960 | 1155844 |
| Aug 15, 2018 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3007426960 | 1062163 |
Form 483s FDA has published for this site
- Oct 5, 2021: Form 483 to Westlab Pharmacy, Inc., published Sep 27, 2022. fda.gov
- Aug 15, 2018: Form 483 to Westlab Pharmacy, Inc., published Apr 30, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 9 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 15, 2018: 9 observations
- Firm on the cover
- Westlab Pharmacy, Inc. dba Westlab, 4410 W. Newberry Rd, Ste A5 Pharmacy, Gainesville, FL 32607-2290 Producer of sterile and non- sterile drug products
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, F L 3275
- Matched to this page by
- firm name, city and state on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The ISO 5 classified aseptic processing area was located within a non-classified room (segregated production area).
Specifically, your firm's ISO 5 <Redacted B4> , which is used to produce mitomycin and cyclosporine drug products, is located in a non-classified room. The following Lots were produced in the-between 5/14/18-08/14/18:
1. Mitomycin Opth 0.02%, Lot 06152018@13
2. Cyclosporin Aqueous 0.5% solution, Lot 0613201 8@43
3. Cyclosporin Aqueous 1 % solution, Lot 06252018@45
4. Cyclosporin Aqueous 1 % solution, Lot 07262018@7
Observation 2
Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically, on 08/06/18, during a medial fill, I observed the ISO 5 Laminar Airflow Workstation (LAFW) was cleaned using non-sterile wipes prior to the media fill. The non-sterile wipes were maintained in the ISO 7 clean room during production.
In addition, your firm utilizes the following non-sterile products to clean the IS05 LAFW and the ISO 5 -:
(b) (4)
1. <Redacted B4>
2. <Redacted B4>
3. <Redacted B4>
Observation 3
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically, your fnm used non-phannaceutical grade (b) ( 4) in the production of Alprostadil 500mcg/mL injectable, Lots 03182018@42 and 07252018@17.
In addition, your firm produced non-sterile products using non-pharmaceutical grade ingredients. Examples include, but are not limited to:
1. Vancomycin/Water 250mg/mL solution, Lot 07022018@53
2. Tetracaine HCL 0.5% Spray, Lot 07022018@ 17
3. Amikacin/Dexamethasone Otic 1/0.1% solution, Lot 07022018@76
4. Estradiol/Estriol/Prog/Test (Raspbeny) 0.4/0.6/50/1 MG Troche, Lot 07022018@3
5. Estradiol/Estriol 0.6/1.4MG Trits, Lot 07022018@1
Observation 4
Personnel engaged in aseptic processing were observed with exposed hands.
Specifically, an operator was observed donning sterile gloves inside the ISO 5 LAFW prior to the media fill 011 08/06/18.
Observation 5
The ISO 5 classified aseptic processing areas had difficult to clean equipment or surface.
Specifically, on 08/08/18, I observed uncovered, exposed light fixtures inside the ISO 5 LAFW during the production of Dexamethasone 24mg/mL injectable, Lot 08082018@30 and EDTA Opth 1.5% solution, Lot 08082018@31.
Observation 6
Written procedures are lacking which describe in sufficient detail the identification, sampling, testing, approval and rejection of components, drng product containers and closures.
Specifically, your firm's procedure, SOP 6.010, Product Procurement, Receipt and Inspection, Version 1, Effective 12/20/12, lack's written procedures for the sampling, identity testing, and approval or rejection of components, containers, and closures used in the production of non-sterile drug products. In addition, your firm does not perform identity testing on the active ingredients used in the production of non-sterile drug products. Examples include, but am not limited to:
1. Acetylcysteine, USP, Lot <Redacted B4>LotlUJlllJ
3. Progesterone USP Micronized Powder, Lot <Redacted B4> (b)(4)
Observation 7
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically, your firm has failed to perform testing for identity and strength for non-sterile finished drug products. Examples include, but are not limited to:
1. Progesterone 200mg G.R. CAPS, Lot 07252018@3
2. Acetylcystine Oral 20% Na, Lot 07182018@8
3. Aminocaproic Acid 250mg/mL solution, Lot 07112018@45
Observation 8
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Specifically, your firm has failed to perform stability testing for its non-sterile drug products. Examples include, but are not limited to:
1. The beyond use date (BUD) for Aminocaproic Acid 250mg/mL solution, Lot 07112018@45 is 180 days.
2. The BUD for Acetylcystine Oral 20% Na, Lot 07182018@8 is 60 days.
3. The BUD for Progesterone 200mg G.R Caps. Lot 07252018@3 is 180 days.
Observation 9
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.
Specifically, on 01/05/17 your firm documented an actionable number of CFUs (colony forming units) in the ISO 5 LAFW (laminar airflow workbench). Upon retest on 01/10/17, an actionable number of CFUs were documented. A negative surface sample was not detected until 01/24/17. A total of <Redacted B4> lots were produce from 01/05/17-01/24/17 in the ISO 5 LAFW with no product evaluation performed.
Linked 483s whose text is not shown
- Oct 5, 2021: FDA document 159977: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH11979 | Pharmacy | WESTLAB PHARMACY INC (dba WESTLAB PHARMACY) | GAINESVILLE | Clear |
| PH27985 | Pharmacy | WESTLAB PHARMACY INC (dba WESTLAB PHARMACY) | GAINESVILLE | Clear |
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 5686 | OSP | Westlab Pharmacy Inc. | Gainesville, FL | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054015792 | LICENSED PHARMACY | WESTLAB PHARMACY INC | GAINESVILLE, FL | NOT RENEWED |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0000843 | NONRESIDENT PHARMACY | WESTLAB PHARMACY INC | GAINESVILLE, FL | ACTIVE (CURRENT) |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.